Respiratory diseases refers to pathological condition affecting lungs and other parts of the respiratory system. Asthma and COPD are the two most common respiratory diseases. Chronic Obstructive Pulmonary Disease (COPD) term is collectively used to describe chronic lung diseases that cause limitations in lung airflow. Asthma is also a chronic lung disease that inflames and narrows the airways. Treatment paradigm of Asthma and COPD therapeutics comprises of anti-inflammatory drugs such as Corticosteroids, Bronchodilator Monotherapy such as Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), combination drugs, etc. Choice of therapeutics depends upon severity of the disease.
Asthma and COPD are leading chronic respiratory diseases with huge economic burden in both developed and developing countries. The disease represents a lucrative market due to continuous rise in prevalence of respiratory diseases, increasing environmental pollution, government initiatives, rise in number of smokers and growing geriatric population. However, the market faces several challenges due to stringent regulatory compliance, patent expiration of blockbuster drugs and associated side-effects of various therapeutics.
The report “Global Asthma & COPD Therapeutics Market (By Type - Anti-inflammatory drugs (Inhaled Corticosteroids (ICS), Bronchodilator Monotherapy (Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), Others; By Nation – The US, Germany, France, Japan & China)) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global Asthma & COPD market with market segmentation done across major therapeutic areas such as Anti-inflammatory drugs, Bronchodilator Monotherapy and Others. Country analysis is done across various markets in the US, Germany, France, Japan & China. Future forecasts of Asthma & COPD Therapeutics market overall and across various sub-markets has been provided in the report till 2025. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global asthma and COPD therapeutics market include AstraZeneca plc, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Novartis AG, Merck & Co., Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global asthma and COPD therapeutics market.
Global Asthma & COPD Therapeutics Market (By Type - Anti-inflammatory drugs (Inhaled Corticosteroids (ICS), Bronchodilator Monotherapy (Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), Others; By Nation – The US, Germany, France, Japan & China)) Market Outlook 2025
Respiratory diseases refers to pathological condition affecting lungs and other parts of the respiratory system. Asthma and COPD are the two most common respiratory diseases. Chronic Obstructive Pulmonary Disease (COPD) term is collectively used to describe chronic lung diseases that cause limitations in lung airflow. Asthma is also a chronic lung disease that inflames and narrows the airways. Treatment paradigm of Asthma and COPD therapeutics comprises of anti-inflammatory drugs such as Corticosteroids, Bronchodilator Monotherapy such as Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), combination drugs, etc. Choice of therapeutics depends upon severity of the disease.
Asthma and COPD are leading chronic respiratory diseases with huge economic burden in both developed and developing countries. The disease represents a lucrative market due to continuous rise in prevalence of respiratory diseases, increasing environmental pollution, government initiatives, rise in number of smokers and growing geriatric population. However, the market faces several challenges due to stringent regulatory compliance, patent expiration of blockbuster drugs and associated side-effects of various therapeutics.
The report “Global Asthma & COPD Therapeutics Market (By Type - Anti-inflammatory drugs (Inhaled Corticosteroids (ICS), Bronchodilator Monotherapy (Short-acting beta2-agonist (SABAs), Long-acting beta2-agonist (LABAs)), Others; By Nation – The US, Germany, France, Japan & China)) Market Outlook 2025” provides in-depth analysis of the current scenario, detailed market outlook of the global Asthma & COPD market with market segmentation done across major therapeutic areas such as Anti-inflammatory drugs, Bronchodilator Monotherapy and Others. Country analysis is done across various markets in the US, Germany, France, Japan & China. Future forecasts of Asthma & COPD Therapeutics market overall and across various sub-markets has been provided in the report till 2025. Furthermore, major industry players have been prudently analyzed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the global asthma and COPD therapeutics market include AstraZeneca plc, GlaxoSmithKline plc, F. Hoffmann-La Roche AG, Novartis AG, Merck & Co., Inc., among others. These players are profiled herein based on attributes such as business overview, product segments and financial analysis. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global asthma and COPD therapeutics market.
1. Executive Summary
2. Research Methodology
3. Respiratory Diseases
3.1 Background
3.2 Types
3.3 Asthma
3.3.1 Overview
3.3.2 Treatment
COPD
3.4.1 Overview
3.4.2 Treatment
4. Market Analysis
4.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Disease
4.2.2 Market Share by Segments
4.2.3 Market Share by Therapeutic Classes
Figure: Global Asthma & COPD Market Share by Therapeutic Classes (2018)
4.2.4 Market Share by Nations
5. Treatment
5.1 Anti-inflammatory drugs
5.1.1 Inhaled Corticosteroids (ICS)
5.1.1.1 Overview
5.1.1.2 Market Sizing (Actual & Forecasted)
5.2 Bronchodilator Monotherapy
5.2.1 Long Acting Beta Agonists (LABA)
5.2.1.1 Overview
5.2.1.1 Market Sizing (Actual & Forecasted)
5.2.2 Short Acting Beta Agonists (SABA)
5.2.2.1 Overview
5.2.2.2 Market Sizing (Actual & Forecasted)
5.3 Others
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
6. Country Analysis
6.1 The US
6.1.1 Market Sizing (Actual & Forecasted)
6.2 Germany
6.2.1 Market Sizing (Actual & Forecasted)
6.3 France
6.3.1 Market Sizing (Actual & Forecasted)
6.4 Japan
6.4.1 Market Sizing (Actual & Forecasted)
6.5 China
6.5.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Connected Health Solutions
7.1.2 Higher Demand for Combination Therapies
7.1.3 Advent of Stem Cell Therapy
7.2 Growth Drivers
7.2.1 Prevalence of Respiratory Diseases
7.2.2 Environmental Pollution
7.2.3 Government Impetus
7.2.4 Rise in Number of Smokers
7.2.5 Growing Geriatric Population
7.3 Challenges
7.3.1 Stringent Regulatory Compliance
7.3.2 Patent Expiration of Drugs
7.3.3 Side-Effects of Drugs
8. Competitive Landscape
8.1 Drugs Clinical Pipeline
8.2 Financial Analysis
8.3 Market Share Analysis
9. Company Profiles
9.1 AstraZeneca plc
9.2 GlaxoSmithKline plc
9.3 F. Hoffmann-La Roche AG
9.4 Novartis AG
9.5 Merck & Co., Inc.
List of Tables
Table 1: Difference between Asthma & COPD Disease Diagnosis
Table 2: COPD Treatment Therapeutics
Table 3: COPD Prevalence by Region
Table 4: Asthma Drugs Clinical Pipeline
Table 5: Market Opportunity of Various Asthma & COPD Drugs
Table 6: Global COPD & Asthma Drugs Manufacturers Revenue Comparison, FY2016-FY2018 (US$ Billions)
Table 7: Global COPD & Asthma Drugs Manufacturers Financial Analysis (FY2018)
Table 8: AstraZeneca plc Asthma & COPD Clinical Pipeline
Table 9: GlaxoSmithKline plc Asthma & COPD Clinical Pipeline
Table 10: GlaxoSmithKline plc Sales of Various Respiratory Drugs, FY2017-FY2024E (US$ Million)
Table 11: Novartis AG Asthma & COPD Clinical Pipeline
Table 12: Merck & Co., Inc. Asthma & COPD Clinical Pipeline
List of Figures
Figure 1: Rockville Research – Research Methodology
Figure 2: Classification of Respiratory Diseases
Figure 3: Economic Burden of Lung Diseases – COPD & Asthma
Figure 4: Asthma Phenotypes and Endotypes
Figure 5: Physiopathology of Asthma Disease
Figure 6: Treatment Paradigm of Asthma
Figure 7: Mechanism and Action of Biological and Oral Asthma Products
Figure 8: Therapeutic Intervention of Chronic Obstructive Pulmonary Disease
Figure 9: Global Asthma & COPD Market Size by Value, 2016-25E (US$ Billions)
Figure 10: Global Asthma & COPD Market Share by Disease (2018)
Figure 11: Global Asthma & COPD Market Share by Segments (2018)
Figure 12: Global Asthma & COPD Market Share by Therapeutic Classes (2018)
Figure 13: Global Asthma and COPD Therapies Market Share by Nations (2018)
Figure 14: Anti-IL13 and 4 Receptor Interactions
Figure 15: Global Asthma & COPD Therapeutics - Inhaled Corticosteroids (ICS) Market Size by Value, 2017-25E (US$ Millions)
Figure 16: Global Asthma & COPD Therapeutics - Long Acting Beta Agonists (LABA) Market Size by Value, 2017-25E (US$ Millions)
Figure 17: Global Asthma & COPD Therapeutics - Short Acting Beta Agonists (SABA) Market Size by Value, 2017-25E (US$ Millions)
Figure 18: Global Asthma & COPD Therapeutics – ‘Others’ Market Size by Value, 2017-25E (US$ Millions)
Figure 19: The US Asthma & COPD Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 20: Germany Asthma & COPD Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 21: France Asthma & COPD Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 22: Japan Asthma & COPD Drugs Market Size by Value, 2016-25E (US$ Billions)
Figure 23: China Asthma & COPD Drugs Market Size by Value, 2016-25E (US$ Billions)
Table 2: Clinical Trials of Use of Stem Cells for COPD
Figure 24: Global Prevalence of Respiratory Diseases, 1990 vs. 2015 (%)
Figure 25: Global Death Rates from Air Pollution, 2013-17 (per 100,000 individuals)
Figure 26: Major Health Impacts of Air Pollution, 2017 (%)
Figure 27: Number of Smokers Worldwide, 2012-18 (Million)
Figure 28: Age-Stratified Prevalence of Chronic Obstructive Pulmonary Disease (COPD) in the US, 2017
Figure 29: Global Asthma & COPD Therapeutics – LABA/ICS Market Share by Drugs (2018)
Figure 30: AstraZeneca plc Revenue by Business Segment (FY2018)
Figure 31: AstraZeneca plc Net Sales, FY2015-FY2018 (US$ Billions)
Figure 32: GlaxoSmithKline plc Revenue by Business Segment (FY2018)
Figure 33: GlaxoSmithKline plc Net Sales, FY2015-FY2018 (US$ Billions)
Figure 34: GlaxoSmithKline plc Respiratory Drugs Sales, FY2017-FY2024E (US$ Million)
Figure 35: F. Hoffmann-La Roche AG Revenue by Business Segment (FY2018)
Figure 36: F. Hoffmann-La Roche AG Net Sales, FY2015-FY2018 (US$ Billions)
Figure 37: Novartis AG Revenue by Business Segment (FY2018)
Figure 38: Novartis AG Respiratory Drugs Sales, FY2016-FY202E (US$ Billions)
Figure 39: Merck & Co., Inc. Revenue by Business Segment (FY2018)
Figure 40: Merck & Co., Inc. Net Sales, FY2014-Y2018 (US$ Billions)
1. AstraZeneca plc
2. GlaxoSmithKline plc
3. F. Hoffmann-La Roche AG
4. Novartis AG
5. Merck & Co., Inc.,
*If Applicable.
